Telix Pharmaceuticals Logo
Telix Pharmaceuticals Logo
  • Our Company
    • Our Company
    • Purpose, Mission & Values
    • Board & Management
    • Our Technology
    • Sustainability
  • Our Portfolio
    • Our Portfolio
    • Disease Areas
      • Prostate Cancer
      • Kidney Cancer
      • Brain Cancer
      • Musculo-skeletal cancers
    • Clinical Trials
    • Illuccix® & Gozellix®
    • Pipeline
    • Research & Innovation
  • Investor Centre
  • News & Views
  • Careers
    • Careers
    • Find a job
Header Image Frame Header Image Frame

Home News & Views

News & Views

News & Views

Telix to Present at Jefferies Healthcare Conference

Events, News,

Telix today advises that Dr Christian Behrenbruch, Managing Director and Group CEO, will be presenting at the Jefferies Healthcare Conference being held in New York from June 7 to June 9, 2023. The presentation will take place on Wednesday…

Read more

Telix to Host Briefing with U.S. Leadership Team and Key Opinion Leaders to Highlight Innovation in Urology

Events, News,

Telix today announces it will host an education session for investors on Wednesday, June 21, 2023, at The Yale Club in New York City, from 8.30am – 12.30pm EDT.  Institutional investors, analysts and company guests are cordially…

Read more

Telix at ANZSNM 2023

Events, News,

Join Telix in Adelaide, South Australia, for the 53rd Annual Scientific Meeting of the Australian and New Zealand Society of Nuclear Medicine from the 26th to the 28th of May. We…

Read more

Telix AGM 2023

ASX, News,

Telix’s 2023 AGM was held on Wednesday, 24th May 2023 at The Events Centre in Melbourne, Australia and…

Read more

Telix to Supply Bayer with Illuccix® for Global Phase III Prostate Cancer Study

Clinical, News,

Telix today announces that it has entered into an agreement with Bayer AG (Bayer) to supply Illuccix® (TLX591-CDx, kit for the preparation of gallium Ga 68 gozetotide injection)[1] for the…

Read more

First Patients in Canada Imaged with Illuccix®: Now Commercially Available Nationwide | Premiers Patients Canadiens à Bénéficier de l’imagerie avec Illuccix®: Maintenant Disponible sur le Marché National

News,

Telix today announces first patients have been imaged in Canada with its commercially available prostate cancer imaging agent, Illuccix® [kit for the preparation of gallium (68Ga) PSMA-11 for intravenous…

Read more

ZIRCON Phase III Kidney Cancer Imaging Study Presented at AUA: New Data Confirms Efficacy in Masses 2cm or Smaller

ASX, News,

Telix today announces additional positive results from its completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (ClinicalTrials.gov Identifier:…

Read more

Telix to Showcase Innovation in Urology at AUA Annual Meeting, including New ZIRCON Phase III Data in Very Small Renal Masses

Events, News,

Telix will showcase further detailed analyses from the Company’s completed pivotal Phase III ZIRCON study of TLX250-CDx (89Zr-DFO-girentuximab) in clear cell renal cell carcinoma (ccRCC) (ClinicalTrials.gov Identifier: NCT03849118) will be…

Read more

Telix Accelerates Artificial Intelligence (AI) Development Program with Acquisition of Dedicaid

ASX, News,

Telix today announces the expansion of its artificial intelligence (AI) capability with the signing of an agreement to acquire Vienna-based Dedicaid GmbH (Dedicaid), a spin-off of the Medical University…

Read more

Notice of Annual General Meeting 2023

ASX, News,

Telix is pleased to provide notice that the Annual General Meeting of the Shareholders of Telix Pharmaceuticals Limited (ACN 616 620 369) will be convened on Wednesday 24 May…

Read more
1 … 20 21 22 23 24 … 50

Subscribe

* indicates required

By subscribing, you are agreeing to the terms of our Global Privacy Policy and provide consent to receive updates from Telix”

Telix Pharmaceuticals Logo
  • Our Company
  • Contact
  • Our Portfolio
  • Careers
  • Investor Centre
  • News & Views

© Telix Pharmaceuticals Limited. 55 Flemington Road, North Melbourne, VIC 3051, Australia.

The Telix Pharmaceuticals and the Illuccix name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates – all rights reserved.
This website is intended for corporate communication purposes only and is not intended as promotion or advertising to any audience in any country worldwide.

Privacy Policy. Terms of Use. Cookies Policy. Privacy Settings